Compare TOI & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOI | AVXL |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | 641 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.4M | 289.1M |
| IPO Year | N/A | 2013 |
| Metric | TOI | AVXL |
|---|---|---|
| Price | $3.34 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $6.67 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.15 | N/A |
| Revenue Next Year | $25.77 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $2.61 |
| 52 Week High | $4.88 | $13.99 |
| Indicator | TOI | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 53.72 | 44.57 |
| Support Level | $2.96 | $2.93 |
| Resistance Level | $3.74 | $3.76 |
| Average True Range (ATR) | 0.19 | 0.20 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 52.04 | 44.71 |
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.